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The endogenous pentapept~des, ~u~nkeph~in 
(Tyr-GIy-Cly-Phe-Leu) and Met-enkephalin 
(Tyr-Gly-Gly-Phe-Met), bind to opiate receptors 
[I ,2] and inhibit the electrically-evoked contractions 
of mouse vas deferens and guinea pig ileum [3]. The 
enkephalins are rapidly hydrolyzed by enzymatic 
activities present in brain and in serum; the peptide 
bond between the Tyr and the Gly comprises the 
preferential site of cleavage [4-61. The rapid degra- 
dation probably accounts for the low and transient 
analgesic effect of the e~epha~ns f?]. The 
prevention of this hy~olysis is therefore necessary in 
order to study the interaction of the enkepbalins with 
the opiate receptors. 
The antibiotic puromycin known to inhibit brain 
arylamidase [8], is an effective inhibitor of the 
hydrolysis of enkephalin by brain homogenate 
[9,10]. Here we tested the specificity of the 
puromycin inhibitory activity on the degradation of
enkephdin. In addition, we determined the effect of 
puromyein on the biological activities of enkephalin, 
such as, binding to brain opiate receptors and inhibi- 
tion of the contractions induced by electrical stimula- 
tion of the guinea pig ileum. 
2. Materials and methods 
[5rosyl-3,5-3H]Leu-enkephalin and [sH]etorphine 
were obtained from Amersham Radiochemical Centre; 
puromycin and puromycin aminonucleoside from 
ICN pharmaceuticals; and p-methoxy-L-phenylalanine 
from Sigma. Nitrous acid deaminated puromy~i~ 
~hydroxypuromycin was prepared and purified as in 
44 
Ill ]_ Other materials and crude brain homogenate 
were obtained as in [6]_ 
2.1. ~~2~~~~~ hydroIys& o~Le~-~nk~~~~~~i~ 
Mixtures of labeled and unlabeled Leu-enkephalin 
(40 000 cpm, 0.1 PM final cont.) were incubated for 
10 min at 30% with the specified enzymatic activity 
in final vol. 100 1.11. The respective incubation mixtures 
contained: 
(a) 0.16 fig leucine aminopeptidase in 10 mM Tris- 
HQ {pH 7.5) and 2 mM MgCl,; 
fb) 3 &l rat serum in 10 mM Tris-HCl (PH 7.5); 
fe) 1.7 ~.tg crude brain homogenate in 10 mM Tris- 
HCl fpH 7.5) and 0.1 mg bovine serum albumin/ 
ml. Reactions were stopped by immersing the 
tubes in a boiling water bath for 10 min. The 
liberation of free tyrosine during the reaction 
was assayed as described [6], utilizing columns 
with polystyrene beads (Porapak Q) to which 
enkephalin but not tyrosine is adsorbed. 
2.2. Bindingo3’Leu-enkeph~lin and etorphine to crude 
brain homogenate 
Crude brain homogenate was preincubated for 
30 min at 37% (to destroy endogenous enkephalin~, 
Aliquots of the homogenate (900 pg protein) were 
further incubated in final vol. 250 ~1 containing 
0.18 M sucrose, 25 mM Tris-HCI (pH 7.5)% and 
either 10 nM [t‘y~ososy2-3,5-3H]Leu-enkephalin 
(41 Ci/mmol) or 3 nM [3H]etorphine (30 Cilmmol). 
The samples were incubated for 10 min at 25% 
(enkephalin) or for 30 min at 37°C (etorphine). 
Binding was assayed by filtration on 25 mm GF/B 
@hatman) glass fiber filters. Non-specific binding, 
measured in the presence of 1 PM bvorphanol was 
subtracted from the values obtained. 
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2.3. Guinea pig ileum preparation 
Ileum segments (2-3 cm long) were bathed at 
37°C in Dulbecco modified Eagle’s medium (GIBCO) 
containing 25 mM Hepes buffer (N-2-hydroxyethyl- 
piperazine-N’-2-ethanesulfonic acid) pH 7.4, instead 
of NaHCOs, and gassed with humified air. The ileum 
was stimulated by coaxial electrical stimulation with 
1 ms pulses of 90 V at a frequency of 0.2 Hz. The 
contractions were recorded isotonically under a 
tension of 1 g using a Hewlett Packard 7DCDT-250 
displacement transducer. 
3. Results 
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Fig.1. Thin-layer chromatography of labeled Leuenkephalin 
incubated with rat brain homogenate in the presence and 
absence of puromycin. Incubation mixtures contained: 
0.4 NM labeled enkephalin, 10 mM Tris-HCl (pH 7.4) and 
10 rg brain homogenate/ml. Incubation was stopped by 
boiling. Samples (5 ~1) were chromotographed on silica 
plates in n-butanol-acetic acid-water (4: 1: 1). Sections 
(0.5 cm) were counted for radioactivity. No incubation 
(o -0); 120 mm incubation at 30°C without puromycin 
(A----A); 120 mln incubation with 0.1 mM puromycin 
(e----o). Arrows show location of markers determined 
by fluorescamine spray as in 161. 
Puromycin Concentration (Ml 
Fig.2. The effect of increasing concentrations of puromycin 
on the rate of hydrolysis of Leuenkephalin by leucine 
amlnopeptidase (o -0); rat serum (e- 0); and rat 
brain homogenate (A ---A). The amount of enkephalin 
hydrolyzed in the absence of puromycin was defined as 100 
and was equivalent o 1.5, 2.8 and 1.5 pmol, respectively. 
effective inhibitor of the brain enzymatic activity 
which cleaves L.eu-enkephalin at the Tyr-Gly peptide 
bond. Incubation of [tyro~yZ-3,5-~H]Leu-enkephalin 
with crude brain homogenate yielded free tyrosine 
with the concomitant disappearance of enkephalin as 
revealed by thin-layer chromatography of the reaction 
mixture (fig.1). Puromycin, at 0.1 mM, inhibited the 
hydrolysis of enkephalin almost completely. 
The effect of increasing concentrations of 
puromycin on the rate of enkephalin hydrolysis is 
shown in fig.2. The enzymatic activity in brain 
homogenate was found to be extremely sensitive to 
puromycin. Inhibition of 50% was observed with 0.2 FM 
puromycin (in the presence of 0.1 E.~M Leu-enkephalin). 
Complete inhibition (97-98%) was observed with 
10 E.IM puromycin. Parallel experiments demonstrated 
that bacitracin, a known inhibitor of enkephalin 
hydrolysis, was less potent that puromycin. Bacitracin 
at 2 PM was required to inhibit enkephalin hydrolysis 
by 50% (in the presence of 0.1 PM Leuenkephalin). 
Interestingly, in contrast to the activity present in 
brain homogenate, the aminopeptidase activity 
present in rat serum as well as purified leucine amino- 
peptidase (both shown to cleave enkephalin at the 
45 
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Table 1 
Effect of puromycin and related compounds on the relative 
rate of hydrolysis of Leu-enkephalm by crude 
rat brain homogenate 
Compound added Relative 
hydrolysis 
None 100.0 
Puromycin, 10e4 M 2.6 
Puromycin aminonucleoside, 10e4 M 99.9 
~-Methoxy-L-phenyl~anine, 1 OW4 M 85.9 
Hydroxypuromycin, 10e4 M 99.3 
Tyr-Gly peptide bond) were not affected by 
puromycin. 
The capacity of puromycin to inhibit the hydrolysis 
of enkephalin by brain enzymatic activity was 
dependent on the integrity of the peptide bond 
between the aminonucleoside and the p-methoxy-L- 
phenylalanine moieties of the puromycin molecule. 
Neither the free puromycin aminonucIeoside 
(puromyc~ without the ~-methoxy-~phenylalanine 
residue) nor the ~-me~oxy-phenylal~ine were 
effective as inhibitors of the enzymatic activity in 
brain homogenates (table 1). The N-terminal amino 
group on the p-methoxy-L-phenylalanine moiety of 
puromycin was also found to be essential; since 
hydroxypuromycin, obtained by deamination of 
puromycin with nitrous acid, was ineffective as an 
inhibitor of enkephalin degradation. 
Binding of labeled enkephalin to the opiate 
receptors of brain membranes was increased by the 
addition of puromycin to the incubation mixture. 
The potency of puromycin was especially evident 
with crude brain homogenates. Figure 3 demonstrates 
that the specific binding of enkephalin increased 
15-20-fold upon the addition of 10-100 PM 
puromycin, reaching a spec. binding act. 45 fmol/mg 
protein. Binding of labeled etorphine, a non- 
hydrolyzable opiate alkaloid with high affinity for 
the opiate receptor, was not affected by puromycin 
and reached spec. act. 130 fmol/mg protein. 
Puromycin inhibited the degradation of enkephalin 
by homogenates of guinea pig ileum. In the presence 
of 10 @I puromycin, the rate of hydrolysis was 
reduced by 80%. In another experiment, we tested 
the biological activity of enkephalin exerted upon 
the guinea pig ileum preparation in the presence and 
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Fig.3. The effect of puromycin on the specific binding of 
etorphine or Leuenkephalin to crude brain homogenate. 
absence of puromycin (figA). The addition of 0.2 FM 
~u~~ephalin to the electrica~y-stimulated guinea 
pig preparation in Dulbecco modified Eagle medium 
was found to completely abolish the electrically- 
induced contractions of the ileum (see fig.4A). Unlike 
the known effect of morphine, the inhibitory action 
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Fig.4. Prolongation by puromycin of the depressant effect 
of Leu~nkephalin on the electricaBy-induced contractions of 
the guinea pig ileum. Arrows mark the addition of 0.2 MM 
Leu-enkephalin, 0.1 mM puromycin and 1 ,uM naloxone, 
respectively. 
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found to be short-lived; the intensity of the con- 
tractions gradually increased and within a few minutes 
approached the original evel. Furomycin alone, at 
Cl.1 mM, inhibited the contraction very slightly. On 
the other hand, the presence of the antibiotic greatly 
extended the time during which enkephalin exerted 
its effect (figAB). This effect of enkephalin, both 
in the presence and absence of puromycin, couid be 
reversed by either washing or by the addition of the 
antagonist naloxone. Thus, short treatments with 
puromycin did not detectably damage the potential 
of the ileum to contract electrically nor to be affected 
by the opiates. 
4. Discussion 
We have demonstrated that puromycin inhibits 
the degradation of enkephalin by brain as well as by 
guinea pig ileum homogenates. The integrity of the 
peptide bond in the puromycin molecule and the 
presence of the amino group of the p*methoxy-L 
phenylalanine r sidue were found to be necessary 
requirements for this i~ibition‘ The high potency of 
puromy~in as an inhibitor might well be related to 
the resemblance of the ~-me~oxy-L-phenyl~anine 
residue to the N-terminal region of enkephalin. 
Bacitracin has been used by various laboratories to 
protect enkephalin against degradation and in 
particular, has been included in binding assays 
involving brain homogenates, in order to protect the 
peptide from enzymatic hydrolysis [2,12] I In the 
above work, puromycin was shown to be much more 
potent than bacitracin in preventing this degradation. 
In addition, puromycin at the effective concentra- 
tions did not interfere with the binding of etorphine 
to the opiate receptor, whereas, bacitracin was found 
to inhibit the binding of etorphine (Z.V., in prep- 
aration) as well as the binding of naloxone ]I 21. 
Puromycin, at 30 ,uM, enhanced the specific binding 
of Len-enkephalin to the receptor of rat brain 
homogenates by l&fold, reaching 45 fmol/mg 
protein. This value is 12-times that in [2] for the 
binding of Met-enkephalin tosimilar brain homogenates 
in the presence of bacitracin. Puromycin, therefore, 
should prove a useful reagent for protecting the 
enkephalins against hydrolysis and for studying their 
interaction with the opiate receptors. 
Puromycin can be used to distinguish between the 
various enzymatic activities capable of hydrolyzing 
the Tyr-Gly peptide bond of enkephalin. Puromycin 
at 10 PM inhibited 97% of the hydrolytic activity 
present in rat brain homogenate. On the other hand, it 
did not inhibit the enzyme leucine aminopeptidase, as 
also found [g], nor did it inhibit the hydrolytic 
activity present in rat serum. 
Puromycin and cycloheximide are known to 
inhibit protein synthesis and impair ‘long term’ 
memory [13,14]. We found that unlike puromycin, 
cycloheximide had no effect on the hydrolysis of 
enkephalin [9]* The results therefore suggest that the 
role of puromycin in blocking enkephalin hydrolysis 
is not directly related to the other effects mentioned. 
Recent experiments with various analogs of puromycin 
revealed that the capacity of puromycin to serve as a 
protein synthesis inhibitor can be distinguished from 
its capability to inhibit enkephalin degradation (Z.V,, 
unpublished). 
5. Conclusions 
The antibiotic puromycin is an effective inhibitor 
of the degradation of mu-enkeph~in by enzymatic 
activities present in rat brain homogenates and guinea 
pig ileum. Furomycin does not inhibit the hydrolysis 
of enkephafin by either leucine aminopeptidase or rat 
serum. The protective ffect of puromycin against the 
hydrolysis enhances the specific binding activity of 
Leu-enkephalin to the opiate receptors in brain 
homogenates by several fold. In addition, puromycin 
greatly prolongs the depressant effect of enkephalin 
on the ele~tric~l~~nduced contractions of the guinea 
pig ileum. The effect of puromy~in i  preventive 
enkephal~n hydrolysis is apparentiy unrelated to its 
capacity to block protein synthesis and to impair 
long term memory, 
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